Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.55 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | LIPE | Q05469 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PAM | P19021 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68851 | 0.92 | CYP4Z1 (0.62) | CYP4Z1CYP4F2CYP4A11MAPTLMNA | |
| SCHEMBL10299459 | 0.86 | CYP4Z1 (0.57) | CYP4Z1CYP4F2CYP4A11MAPTLMNA | |
| SCHEMBL1107146 | 0.86 | CYP4Z1 (0.57) | CYP4Z1CYP4F2CYP4A11MAPTLMNA | |
| SCHEMBL6057577 | 0.86 | CYP4F2 (0.59) | CYP4Z1CYP4F2CYP4A11MAPTLMNA | |
| SCHEMBL68930 | 0.86 | CYP4Z1 (0.57) | CYP4Z1CYP4F2CYP4A11MAPTLMNA | |
| SCHEMBL19347765 | 0.85 | CYP4F2 (0.74) | CYP4Z1CYP4F2CYP4A11MAPTLMNA | |
| SCHEMBL18932531 | 0.84 | CYP4Z1 (0.55) | CYP4Z1CYP4F2CYP4A11MAPTLMNA | |
| SCHEMBL5034285 | 0.84 | CYP4Z1 (0.59) | CYP4Z1CYP4F2CYP4A11MAPTLMNA | |
| SCHEMBL5545889 | 0.84 | CYP4Z1 (0.55) | CYP4Z1CYP4F2CYP4A11MAPTLMNA | |
| SCHEMBL1179218 | 0.84 | CYP4Z1 (0.55) | CYP4Z1CYP4F2CYP4A11MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130196964-A1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-08-01 | — | — | US | disclosed |
| US-20110312930-A1 | Aryl compounds with aminoalkyl substituents and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-22 | — | — | US | disclosed |
| CN-102282142-A | Substituted aryl compounds and their use | — | 2011-12-14 | — | — | CN | disclosed |
| US-20110301122-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-08 | — | — | US | disclosed |
| EP-1383769-A4 | 6-SUBSTITUTED PYRAZOLO 3,4-D]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-08-03 | — | — | EP | disclosed |
| EP-1121363-B1 | 6-SUBSTITUTED PYRAZOLO(3,4-d)PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-12-22 | — | — | EP | disclosed |
| EP-1383769-A2 | 6-SUBSTITUTED PYRAZOLO 3,4-D]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2004-01-28 | — | — | EP | disclosed |
| US-6559152-B2 | For therapy of cancer or other proliferative diseases | DUPONT PHARMACEUTICALS COMPANY | 2003-05-06 | — | — | US | disclosed |
| US-6531477-B1 | Treating cancer or other proliferative diseases | DUPONT PHARMACEUTICALS COMPANY | 2003-03-11 | — | — | US | disclosed |
| WO-2002067654-A3 | 6-SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002067654-A2 | 6-SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-09-06 | — | — | WO | disclosed |
| US-20020013328-A1 | 6-Substituted pyrazolo[3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | disclosed |
| EP-1121363-A2 | 6-SUBSTITUTED PYRAZOLO 3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000021926-A2 | 6-SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013328-A1 | 6-Substituted pyrazolo[3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors | CCNK, CCNI, CDK1 | CYP4Z1 1002/4885CYP4F2 2970/4885CYP4A11 1273/4885 |
| US-20110301122-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | HIF1AN, HIF1A, VHL | CYP4Z1 1707/4885CYP4F2 417/4885CYP4A11 449/4885 |
| US-20110312930-A1 | Aryl compounds with aminoalkyl substituents and their use | VHL, HIF1AN, HIF1A | CYP4Z1 2823/4885CYP4F2 722/4885CYP4A11 520/4885 |
| US-20130196964-A1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | HIF1AN, HIF1A, VHL | CYP4Z1 2306/4885CYP4F2 549/4885CYP4A11 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.